- Home
- RIGL vs CLMB Comparison
RIGL vs CLMB Comparison
Compare RIGL & CLMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | CLMB |
|---|---|---|
| Founded | 1996 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 527.7M |
| IPO Year | 2000 | 1996 |
Fundamental Metrics
Financial Performance| Metric | RIGL | CLMB |
|---|---|---|
| Price | $46.86 | $29.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $45.67 | ★ $80.00 |
| AVG Volume (30 Days) | ★ 288.3K | 139.1K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ 1867.68 | 14.29 |
| EPS | ★ 1.32 | 0.48 |
| Revenue | $294,282,000.00 | ★ $652,517,000.00 |
| Revenue This Year | N/A | $7.82 |
| Revenue Next Year | $12.75 | $5.83 |
| P/E Ratio | ★ $35.21 | $57.65 |
| Revenue Growth | ★ 64.15 | 40.14 |
| 52 Week Low | $24.84 | $15.25 |
| 52 Week High | $52.24 | $145.00 |
Technical Indicators
Market Signals| Indicator | RIGL | CLMB |
|---|---|---|
| Relative Strength Index (RSI) | 66.46 | 62.84 |
| Support Level | $40.05 | $23.78 |
| Resistance Level | $49.10 | $112.00 |
| Average True Range (ATR) | 1.92 | 0.95 |
| MACD | 0.36 | -0.11 |
| Stochastic Oscillator | 90.87 | 85.47 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About CLMB Climb Global Solutions Inc.
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, United Kingdom, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.